雷纳Rs2296545变体通过修改阻塞性睡眠呼吸暂停中对甲基荷兰胺的结合亲和力来改善高血压易感性
Hangdong Shen1,2,3, Jundong Yang4,5, Wenjun Xue6
1Department of Otorhinolaryngology Head and Neck Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
概括
血清再生酶水平和特定基因变异 (rs2296545) 与阻塞性睡眠呼吸暂停 (OSA) 患者的高血压有关. 这种遗传变异可能会增加高血压风险,因为它会影响酶与血压调节物质的相互作用.
科学领域:
- 心血管医学 心血管医学
- 遗传学 是一个遗传学.
- 睡眠医学 睡眠医学
背景情况:
- 阻塞性睡眠呼吸暂停 (OSA) 经常与高血压有关,但其与血压调节蛋白质再生酶的关系尚不清楚.
- 研究血清再生酶水平和再生酶中的rs2296545单核酸多态 (SNP) 提供了对OSA高血压机制的洞察力.
研究的目的:
- 探索血清再生酶水平和rs2296545变体与高血压在汉族中国人群中与OSA之间的关联.
- 分析rs2296545对再生酶蛋白结构及其与甲基醇胺的相互作用的影响.
主要方法:
- 在126名OSA受试者中测量了血清再生酶水平;线性回归分析了与OSA特征的相关性.
- 对rs2296545的基因型数据来自4275名使用SNP微阵列的受试者;二元逻辑回归评估了高血压风险.
- 分子动力学模拟和对接评估了野生类型和突变的rs2296545再生酶蛋白质结构和甲醇胺结合.
主要成果:
- 严重的OSA患者表现出显著更高的血清再生酶水平.
- 雷纳酶水平与非OSA个体的血压呈正相关,而在严重OSA患者中则呈负相关.
- rs2296545多态 (CC/GG+CG和CC/CG模型) 与严重的OSA中高血压风险增加,蛋白质结构的改变和catecholamine结合的削弱有关.
结论:
- 血清再生酶水平与血压独立相关.
- rs2296545多态可能会使个体在OSA中易患高血压,因为它会损害雷纳酶的甲醇胺结合能力.
- 这些发现表明OSA患者高血压管理的潜在治疗点.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
511
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
511
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
510
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
510
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
614
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
614
01:17Antihypertensive Drugs: Action of β1 Blockers
327
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
327
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
142
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
142